Protein structure design and recombinant technology
We have used protein structure design technology to design pneumococcal protein antigens. In addition, we have developed novel recombinant strains to produce a new generation pertussis vaccine. We also developed a proprietary cell line to be used for viral vector production.
Our Synthetic biotechnology and process know-how enable us to manufacture a wide range of conjugate vaccines. In addition to commonly used DT and TT carrier proteins, we have a number of carrier proteins including CRM197, which is produced by our proprietary high-yield bacterial strain and used in our MCV candidates. Our wide range of carrier proteins allows us to develop better multi-v